Skip to main content
. 2023 Dec 5;23:487. doi: 10.1186/s12890-023-02798-6

Table 3.

Comparison of HRV detection between patients with or without ICS treatment

All (n = 54) Non-ICS group (n = 26) ICS group (n = 28) p-value
n (%) n (%) n (%)
Viral pathogen detected 45 (83.3%) 23 (88.5%) 22 (78.6%) 0.47
    HRV 33 (61.1%) 21 (80.8%) 12 (42.9%) 0.004*
        HRV-A 16 (29.6%) 9 (34.6%) 7 (25.0%) 0.44
        HRV-B 1 (1.9%) 0 (0.0%) 1 (3.6%) 1.00
        HRV-C 16 (29.6%) 12 (46.2%) 4 (14.3%) 0.01*

ICS inhaled corticosteroids, HRV human rhinovirus

*p < 0.05 by Chi-squared test or Fisher’s exact test between Non-ICS group and ICS group